companiesCompany
SEngine Precision Medicine
Runs the PARIS test: a patient's tumour grown as organoids and screened against 240+ drugs to find options sequencing cannot see.
CLIA-certified in all 50 states and New York CLEP-approved. PARIS uses 3D organoids from any solid tumour to rank drug sensitivity; collaborations with Dana-Farber and Gustave Roussy; about $19M raised through Series A.